Table 2.
Case reports and case series of AIHA in CML patients (TKI was used as part of CML therapy)
| 1st author | Year of publication | Age, years/ | CML phase gender | CML therapy | AIHA onset | Hb, g/dL | AIHA therapy | Duration of therapy | Hb, g/dL − follow-up | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Novaretti M.C. [27] | 2003 | 45/M | Chronic | Imatinib 400 mg for 6 mo, then 600 mg for 6 mo | 11 years post-CML diagnosis, 8 mo post-imatinib | 5.9 | Prednisone (1 mg/kg) | 6 mo (tapered) | 12.1 | Improved |
| Rokicka M. [28] | 2009 | 21/F | Chronic | IFN-α for 7 mo Imatinib for 3 mo Hydroxyurea for 2 yr, then UCBT | 6 mo Post-UCBT AIHA and CAD |
N/A | Methylprednisolone (2–5 mg/kg) IVIg (0.5 g/kg), rituximab (4 doses), mycophenolate Mofetil cyclophosphamide (750 mg/m2/d), plasmapheresis (7 sessions), splenectomy |
- | N/A | Died with hemolysis after 9.5 mo |
| Lewandowski K. [29] | 2016 | 68/M | Chronic | IFN-α + cytosine arabinoside (3 yr), then imatinib (9 yr) | 9 yr post-imatinib | 5.8 | Prednisone (1 mg/kg) | N/A | N/A | Improved |
| Garg S. [30] | 2018 | 43/F | Blast crisis | Imatinib | 15 yr post-CML diagnosis | 3.7 | Prednisolone | N/A | N/A | Improved |
| Cao L. [31] | 2018 | 46/F | Blast crisis | Dasatinib, then allogenic HSCT twice | 7.5 mo post-SCT | 6.1 | Prednisolone (2 mg/kg) IVIg (2 g/kg) Rituximab 375 mg/m2 Bortezomib |
4 Mo | 12 | Improved |
AIHA, autoimmune hemolytic anemia; CML, chronic myeloid leukemia; d, day; Hb, hemoglobin; HSCT, hematopoietic stem cell transplantation; IFN-α, interferon alpha; IVIg, intravenous immunoglobulin; F, female; M, male; mo, month; N/A, not available; SCT, stem cell transplantation; UCBT, umbilical cord blood transplantation; wk, week; yr, year.